SCHEMBL3399892

SCHEMBL3399892

CC(=COS(=O)(=O)O)C(=O)O

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 4/20 0.32
PTGS1 P23219 1/20 0.31
AKR1C3 P42330 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27666581 0.81 APEX1 (0.32) APEX1PTGS1AKR1C3
SCHEMBL5402343 0.77
SCHEMBL1865885 0.71 PTGS1 (0.37) APEX1PTGS1AKR1C3
SCHEMBL1865884 0.71 PTGS1 (0.37) APEX1PTGS1AKR1C3
SCHEMBL16543221 0.70
SCHEMBL4127819 0.70
SCHEMBL12311775 0.70
SCHEMBL12311770 0.70
SCHEMBL167103 0.69
SCHEMBL5998620 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230323142-A1 METHACRYLATED NANOPARTICLES AND RELATED METHOD LI LAN (US) 2023-10-12 US claimed
US-20230127516-A1 REVOKING ACCESS TO A NETWORK NCHAIN LICENSING AG (CH) 2023-04-27 US claimed
US-8716399-B2 Polysaccharide-grafted polyethylenimine as a gene carrier KAOHSIUNG MEDICAL UNIVERSITY (TW) 2014-05-06 US claimed
US-20130177976-A1 COMBINATION OF CATIONIC POLYMERS AND POLYSACCHARIDES NANOPARTICLES AS A GENE CARRIER KAOHSIUNG MEDICAL UNIVERSITY (TW) 2013-07-11 US claimed
US-20130030119-A1 POLYSACCHARIDE-GRAFTED POLYETHYLENIMINE AS A GENE CARRIER KAOHSIUNG MEDICAL UNIVERSITY (TW) 2013-01-31 US claimed
US-20230323142-A1 METHACRYLATED NANOPARTICLES AND RELATED METHOD LI LAN (US) 2023-10-12 US disclosed
WO-2020196990-A1 IN VITRO OSTEOARTHRITIS MODEL AND METHOD FOR SCREENING FOR OSTEOARTHRITIS TREATMENT AGENT BY USING SAME 박동휘 2020-10-01 WO disclosed
US-20180223329-A1 CROSS-LINKED POLYMER MATRICES, AND METHODS OF MAKING AND USING SAME UNIV JOHNS HOPKINS (US) 2018-08-09 US disclosed
US-20160228610-A1 TISSUE ENGINEERING USING PROGENITOR CELLS TO CATALYZE TISSUE FORMATION BY PRIMARY CELLS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2016-08-11 US disclosed
US-20140288022-A1 CROSS-LINKED POLYMER MATRICES, AND METHODS OF MAKING AND USING SAME THE JOHNS HOPKINS UNIVERSITY (US) 2014-09-25 US disclosed
US-20140219972-A1 TISSUE ENGINEERING USING PROGENITOR CELLS TO CATALYZE TISSUE FORMATION BY PRIMARY CELLS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2014-08-07 US disclosed
US-8742013-B2 Synthesis of lipoamide-grafted high molecular compound and method therefor Seoul National University of Technology Center for Industrial Collaboration (KR) 2014-06-03 US disclosed
US-20100272761-A1 SYNTHESIS OF LIPOAMIDE-GRAFTED HIGH MOLECULAR COMPOUND AND METHOD THEREFOR Seoul National University of Technology Center for Industrial Collaboration (KR) 2010-10-28 US disclosed
US-20090076606-A1 COATED MEDICAL DEVICE BIOMET, INC. 2009-03-19 US disclosed
EP-1863404-A2 COATED MEDICAL DEVICE Cartilix, Inc. (US) 2007-12-12 EP disclosed
US-20070098675-A1 CROSS-LINKED POLYMER MATRICES, AND METHODS OF MAKING AND USING SAME JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) 2007-05-03 US disclosed
EP-1558216-A4 CROSS-LINKED POLYMER MATRICES, AND METHODS OF MAKING AND USING SAME UNIV JOHNS HOPKINS MED (US) 2007-01-03 EP disclosed
WO-2006105161-A2 COATED MEDICAL DEVICE CARTILIX, INC. (US) 2006-10-05 WO disclosed
EP-1558216-A2 CROSS-LINKED POLYMER MATRICES, AND METHODS OF MAKING AND USING SAME Johns Hopkins University School of Medicine (US) 2005-08-03 EP disclosed
WO-2004029137-A2 CROSS-LINKED POLYMER MATRICES, AND METHODS OF MAKING AND USING SAME JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) 2004-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070098675-A1 CROSS-LINKED POLYMER MATRICES, AND METHODS OF MAKING AND USING SAME MMP13, MMP1, MMP10 APEX1 1541/4885PTGS1 544/4885AKR1C3 1863/4885
US-20100272761-A1 SYNTHESIS OF LIPOAMIDE-GRAFTED HIGH MOLECULAR COMPOUND AND METHOD THEREFOR HDGF, HASPIN, LIPE APEX1 4120/4885PTGS1 697/4885AKR1C3 3360/4885
US-20180223329-A1 CROSS-LINKED POLYMER MATRICES, AND METHODS OF MAKING AND USING SAME MMP13, MMP1, MMP10 APEX1 1541/4885PTGS1 544/4885AKR1C3 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.